Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography

키워드

참고문헌 (204)

1. Meinardi MT, "Long-term chemotherapy-related cardiovascular morbidity", Cancer Treat Rev, 26, pp.429~447 (2000)[DOI]
2. Yeh ET, "Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management", J Am Coll Cardiol, 53, pp.2231~2247 (2009)[DOI]
3. Zamorano JL, "ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)", Eur J Heart Fail, 19, pp.9~42 (2016)
4. Curigliano G, "Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines", Ann Oncol, 23(Suppl 7), pp.vii155~vii166 (2012)
5. Maurea N, "A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology", J Cardiovasc Med (Hagerstown), 17(Suppl 1), pp.S93~S104 (2016)[DOI]
6. Albini A, "Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention", J Natl Cancer Inst, 102, pp.14~25 (2010)[DOI]
7. Groarke JD, "Anthracycline cardiotoxicity: a new paradigm for an old classic", Circulation, 131, pp.1946~1949 (2015)[DOI]
8. Distefano G, "Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy", Ital J Pediatr, 35, pp.37~ (2009)[DOI]
9. Ewer MS, "Cancer and the heart", pp.11~41 (2013), People's Medical Publishing House - USA, Ltd
10. Lyu YL, "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane", Cancer Res, 67, pp.8839~8846 (2007)[DOI]
11. Schimmel KJ, "Cardiotoxicity of cytotoxic drugs", Cancer Treat Rev, 30, pp.181~191 (2004)[DOI]
12. Kosmas C, "Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study", J Cancer Res Clin Oncol, 134, pp.75~82 (2008)
13. Meyer CC, "Symptomatic cardiotoxicity associated with 5-fluorouracil", Pharmacotherapy, 17, pp.729~736 (1997)
14. Khouri MG, "Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues", Circulation, 126, pp.2749~2763 (2012)[DOI]
15. Plana JC, "Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 27, pp.911~939 (2014)[DOI]
16. Ewer MS, "Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity", J Clin Oncol, 23, pp.2900~2902 (2005)[DOI]
17. Woo-Baek Chung, "Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity", The Korean Journal of Internal Medicine, 31(4), pp.625~633 (2016), 대한내과학회[DOI]
18. Scherrer-Crosbie M, "Anticancer treatments and cardiotoxicity mechanisms, diagnostic, and therapeutic interventions", pp.35~38 (2016), Elsvier
19. Youn HJ, "Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment", Mol Cell Biochem, 270, pp.13~19 (2005)[DOI]
20. Taniguchi I, "Clinical significance of cyclophosphamide-induced cardiotoxicity", Intern Med, 44, pp.89~90 (2005)[DOI]
21. O'Connell TX, "Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide", Cancer Res, 34, pp.1586~1591 (1974)
22. Braverman AC, "Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens", J Clin Oncol, 9, pp.1215~1223 (1991)[DOI]
23. Kandylis K, "Ifosfamide cardiotoxicity in humans", Cancer Chemother Pharmacol, 24, pp.395~396 (1989)
24. Madeddu C, "Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy", J Cardiovasc Med (Hagerstown), 17(Suppl 1), pp.e12~e18 (2016)[DOI]
25. Ewer SM, "Cardiotoxicity profile of trastuzumab", Drug Saf, 31, pp.459~467 (2008)[DOI]
26. Nowsheen S, "Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer", Curr Breast Cancer Rep, 9, pp.173~182 (2017)[DOI]
27. Force T, "Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition", Nat Rev Cancer, 7, pp.332~344 (2007)[DOI]
28. Chen ZI, "Cardiotoxicity associated with targeted cancer therapies", Mol Clin Oncol, 4, pp.675~681 (2016)[DOI]
29. Lankhorst S, "Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress", Antioxid Redox Signal, 20, pp.135~145 (2014)[DOI]
30. Pandey AK, "Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease", Hypertension, 71, pp.e1~e8 (2018)[DOI]
31. Scappaticci FA, "Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab", J Natl Cancer Inst, 99, pp.1232~1239 (2007)[DOI]
32. Samuels BL, "Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy", Cancer Chemother Pharmacol, 19, pp.253~256 (1987)
33. Lu JI, "Acute coronary syndrome secondary to fluorouracil infusion", J Clin Oncol, 24, pp.2959~2960 (2006)[DOI]
34. Frickhofen N, "Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil", Ann Oncol, 13, pp.797~801 (2002)[DOI]
35. Polk A, "A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity", BMC Pharmacol Toxicol, 15, pp.47~ (2014)[DOI]
36. Schober C, "Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer", Cancer, 72, pp.2242~2247 (1993)[DOI]
37. Ward S, "Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation", Health Technol Assess, 11, pp.1~144 (2007)
38. Franco TH, "Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer", Ther Clin Risk Manag, 4, pp.1367~1370 (2008)[DOI]
39. Tamargo J, "Cancer chemotherapy and cardiac arrhythmias: a review", Drug Saf, 38, pp.129~152 (2015)[DOI]
40. Priori SG, "2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)", Eur Heart J, 36, pp.2793~2867 (2015)[DOI]
41. Vorchheimer DA, "What is QT interval prolongation?", J Fam Pract, (Suppl), pp.S4~S7 (2005)
42. Roboz GJ, "Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide", J Clin Oncol, 32, pp.3723~3728 (2014)[DOI]
43. Markman TM, "Arrhythmia and electrophysiological effects of chemotherapy: a review", Oncology, 91, pp.61~68 (2016)[DOI]
44. Ifran A, "High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation", Am J Hematol, 80, pp.247~ (2005)[DOI]
45. Rowinsky EK, "Cardiac disturbances during the administration of taxol", J Clin Oncol, 9, pp.1704~1712 (1991)[DOI]
46. Kamineni P, "Cardiotoxicities of paclitaxel in African Americans", J Natl Med Assoc, 96, pp.995~ (2004)
47. McGuire WP, "Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms", Ann Intern Med, 111, pp.273~279 (1989)[DOI]
48. Jain M, "Chemotherapy agents and hypertension: a focus on angiogenesis blockade", Curr Hypertens Rep, 9, pp.320~328 (2007)[DOI]
49. Colt JS, "Hypertension and risk of renal cell carcinoma among white and black Americans", Epidemiology, 22, pp.797~804 (2011)
50. Ferrara N, "The biology of VEGF and its receptors", Nat Med, 9, pp.669~676 (2003)[DOI]
51. Milan A, "Arterial hypertension and cancer", Int J Cancer, 134, pp.2269~2277 (2014)[DOI]
52. Izzedine H, "Management of hypertension in angiogenesis inhibitor-treated patients", Ann Oncol, 20, pp.807~815 (2009)[DOI]
53. Chu TF, "Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib", Lancet, 370, pp.2011~2019 (2007)[DOI]
54. Aparicio-Gallego G, "Molecular basis of hypertension side effects induced by sunitinib", Anticancer Drugs, 22, pp.1~8 (2011)[DOI]
55. Eremina V, "VEGF inhibition and renal thrombotic microangiopathy", N Engl J Med, 358, pp.1129~1136 (2008)[DOI]
56. Qi WX, "Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis", Br J Clin Pharmacol, 76, pp.348~357 (2013)[DOI]
57. Di Nisio M, "Arterial thrombosis in ambulatory cancer patients treated with chemotherapy", Thromb Res, 127, pp.382~383 (2011)[DOI]
58. Choueiri TK, "Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials", J Clin Oncol, 28, pp.2280~2285 (2010)[DOI]
59. Schutz FA, "Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes", Ann Oncol, 22, pp.1404~1412 (2011)[DOI]
60. Riedl J, "Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS)", Thromb Haemost, 111, pp.670~678 (2014)[DOI]
61. Ay C, "Cancer-associated venous thromboembolism: burden, mechanisms, and management", Thromb Haemost, 117, pp.219~230 (2017)[DOI]
62. Khorana AA, "Development and validation of a predictive model for chemotherapy-associated thrombosis", Blood, 111, pp.4902~4907 (2008)[DOI]
63. 이윤규, "Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer", Cancer Research and Treatment, 47(4), pp.670~675 (2015), 대한암학회[DOI]
64. Guignabert C, "Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension", J Clin Invest, 126, pp.3207~3218 (2016)[DOI]
65. Montani D, "Pulmonary arterial hypertension in patients treated by dasatinib", Circulation, 125, pp.2128~2137 (2012)[DOI]
66. Alias S, "Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension", Arterioscler Thromb Vasc Biol, 34, pp.810~819 (2014)[DOI]
67. Pohjola-Sintonen S, "Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease", Cancer, 60, pp.31~37 (1987)[DOI]
68. Hayek ER, "Acute doxorubicin cardiotoxicity", N Engl J Med, 352, pp.2456~2457 (2005)[DOI]
69. Bristow MR, "Early anthracycline cardiotoxicity", Am J Med, 65, pp.823~832 (1978)[DOI]
70. 정우백, "Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with Breast Cancer", Journal of Breast Cancer, 16(2), pp.178~183 (2013), 한국유방암학회
71. Lotrionte M, "Review and metaanalysis of incidence and clinical predictors of anthracycline cardiotoxicity", Am J Cardiol, 112, pp.1980~1984 (2013)[DOI]
72. Suter TM, "Cancer drugs and the heart: importance and management", Eur Heart J, 34, pp.1102~1111 (2013)[DOI]
73. Bickford CL, "Cancer and the heart", pp.69~82 (2013), People's Medical Publishing House - USA, Ltd
74. Floyd JD, "Cardiotoxicity of cancer therapy", J Clin Oncol, 23, pp.7685~7696 (2005)[DOI]
75. Czaykowski PM, "High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy", J Urol, 160(6 Pt 1), pp.2021~2024 (1998)[DOI]
76. 김상민, "A Case of Severe Coronary Spasm Associated with 5-Fluorouracil Chemotherapy", The Korean Journal of Internal Medicine, 27(3), pp.342~345 (2012), 대한내과학회[DOI]
77. Seidman A, "Cardiac dysfunction in the trastuzumab clinical trials experience", J Clin Oncol, 20, pp.1215~1221 (2002)[DOI]
78. Romond EH, "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer", N Engl J Med, 353, pp.1673~1684 (2005)[DOI]
79. Perez EA, "Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial", J Clin Oncol, 26, pp.1231~1238 (2008)[DOI]
80. Guarneri V, "Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience", J Clin Oncol, 24, pp.4107~4115 (2006)[DOI]
81. Gianni L, "Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes", Cardiovasc Toxicol, 7, pp.67~71 (2007)[DOI]
82. Guglin M, "Trastuzumab-induced cardiomyopathy", J Card Fail, 14, pp.437~444 (2008)[DOI]
83. Tan-Chiu E, "Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31", J Clin Oncol, 23, pp.7811~7819 (2005)[DOI]
84. Cardinale D, "Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation", J Clin Oncol, 28, pp.3910~3916 (2010)[DOI]
85. Ky B, "Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab", J Am Coll Cardiol, 63, pp.809~816 (2014)[DOI]
86. Thavendiranathan P, "Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review", J Am Coll Cardiol, 63(25), pp.2751~2768 (2014)[DOI]
87. Escudier B, "Sorafenib in advanced clear-cell renal-cell carcinoma", N Engl J Med, 356, pp.125~134 (2007)[DOI]
88. Verheul HM, "Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition", Nat Rev Cancer, 7, pp.475~485 (2007)[DOI]
89. Miller K, "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer", N Engl J Med, 357, pp.2666~2676 (2007)[DOI]
90. Miller KD, "Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer", J Clin Oncol, 23, pp.792~799 (2005)[DOI]
91. Elitok A, "Effect of carvedilol on silent anthracyclineinduced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up", Cardiol J, 21, pp.509~515 (2014)[DOI]
92. Gulati G, "Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a <TEX>$2{\time}2$<", TEX> factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol, 2016, pp.37, 1671~1680
93. Kaya MG, "Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study", Int J Cardiol, 167, pp.2306~2310 (2013)[DOI]
94. Cardinale D, "Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy", J Am Coll Cardiol, 55, pp.213~220 (2010)[DOI]
95. Bosch X, "Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)", J Am Coll Cardiol, 61, pp.2355~2362 (2013)[DOI]
96. Kalam K, "Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis", Eur J Cancer, 49, pp.2900~2909 (2013)[DOI]
97. van Dalen EC, "Cardioprotective interventions for cancer patients receiving anthracyclines", Cochrane Database Syst Rev (2011)[DOI]
98. Hensley ML, "American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants", J Clin Oncol, 27, pp.127~145 (2009)[DOI]
99. Acar Z, "Efficiency of atorvastatin in the protection of anthracyclineinduced cardiomyopathy", J Am Coll Cardiol, 58, pp.988~989 (2011)[DOI]
100. Seicean S, "Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study", J Am Coll Cardiol, 60, pp.2384~2390 (2012)[DOI]
101. Chow EJ, "Individual prediction of heart failure among childhood cancer survivors", J Clin Oncol, 33, pp.394~402 (2015)
102. Mendelsohn ME, "Molecular and cellular basis of cardiovascular gender differences", Science, 308, pp.1583~1587 (2005)[DOI]
103. El-Kareh AW, "A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells", Neoplasia, 2, pp.325~338 (2000)[DOI]
104. van Dalen EC, "Different anthracycline derivates for reducing cardiotoxicity in cancer patients", Cochrane Database Syst Rev (2010)[DOI]
105. Seymour LW, "Passive tumor targeting of soluble macromolecules and drug conjugates", Crit Rev Ther Drug Carrier Syst, 9, pp.135~187 (1992)
107. Ezaz G, "Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer", J Am Heart Assoc, 3, pp.e000472~ (2014)[DOI]
108. Witteles RM, "Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?", Heart Fail Clin, 7, pp.333~344 (2011)[DOI]
109. Carver JR, "American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects", J Clin Oncol, 25, pp.3991~4008 (2007)[DOI]
110. Suter TM, "Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial", J Clin Oncol, 25, pp.3859~3865 (2007)[DOI]
111. Jones AL, "Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring", Br J Cancer, 100, pp.684~692 (2009)[DOI]
112. Virani SA, "Canadian Cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy", Can J Cardiol, 32, pp.831~841 (2016)[DOI]
113. Hamo CE, "Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions", Circ Heart Fail, 9, pp.e002843~ (2016)[DOI]
114. Sawaya H, "Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab", Circ Cardiovasc Imaging, 5, pp.596~603 (2012)[DOI]
115. Sawaya H, "Early detection and prediction of cardiotoxicity in chemotherapy-treated patients", Am J Cardiol, 107, pp.1375~1380 (2011)[DOI]
116. Gulati G, "Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab", Curr Heart Fail Rep, 11, pp.366~373 (2014)[DOI]
117. King A, "Global longitudinal strain: a useful everyday measurement?", Echo Res Pract, 3, pp.85~93 (2016)[DOI]
118. Cardinale D, "Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy", Circulation, 109, pp.2749~2754 (2004)[DOI]
119. Sandri MT, "N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?", Clin Chem, 51, pp.1405~1410 (2005)[DOI]
120. Cardinale D, "Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy", J Am Coll Cardiol, 36, pp.517~522 (2000)[DOI]
121. Ledwidge M, "Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial", JAMA, 310, pp.66~74 (2013)[DOI]
122. Wang YD, "Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity", Oncol Lett, 11, pp.3483~3492 (2016)[DOI]
123. Ferlay J, "Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012", Eur J Cancer, 49, pp.1374~1403 (2013)[DOI]
124. Todaro MC, "Cardioncology: state of the heart", Int J Cardiol, 168, pp.680~687 (2013)[DOI]
125. Lancellotti P, "Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography", Eur Heart J Cardiovasc Imaging, 14, pp.721~740 (2013)[DOI]
126. Mor-Avi V, "Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE", EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography, 2011, pp.12, 167~205
127. Negishi K, "Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity", J Am Soc Echocardiogr, 26, pp.493~498 (2013)[DOI]
128. Charbonnel C, "Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity", Eur Heart J Cardiovasc Imaging, 18, pp.392~401 (2017)
129. Ho E, "Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study", Heart, 96, pp.701~707 (2010)[DOI]
130. Greenberg NL, "Doppler-derived myocardial systolic strain rate is a strong index of left ventricular contractility", Circulation, 105, pp.99~105 (2002)[DOI]
131. Voigt JU, "Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI", ASE, Eur Heart J Cardiovasc Imaging, pp.2015, 16[DOI]
132. Hering D, "Echocardiographic features of radiation-associated valvular disease", Am J Cardiol, 92, pp.226~230 (2003)[DOI]
133. Hull MC, "Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy", JAMA, 290, pp.2831~2837 (2003)[DOI]
134. Thavendiranathan P, "Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy", J Am Coll Cardiol, 61, pp.77~84 (2013)[DOI]
135. Thavendiranathan P, "Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review", Circ Cardiovasc Imaging, 6, pp.1080~1091 (2013)[DOI]
136. Cheong BY, "Nephrogenic systemic fibrosis: a concise review for cardiologists", Tex Heart Inst J, 37, pp.508~515 (2010)
137. Friedrich MG, "Cardiovascular magnetic resonance in myocarditis: A JACC White Paper", J Am Coll Cardiol, 53, pp.1475~1487 (2009)[DOI]
138. Fallah-Rad N, "Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy", J Cardiovasc Magn Reson, 10, pp.5~ (2008)[DOI]
139. Tham EB, "Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling", J Cardiovasc Magn Reson, 15, pp.48~ (2013)[DOI]
140. Jordan JH, "Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance", Circ Cardiovasc Imaging, 7, pp.872~879 (2014)[DOI]
141. Wassmuth R, "Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study", Am Heart J, 141, pp.1007~1013 (2001)[DOI]
142. Iles L, "Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping", J Am Coll Cardiol, 52, pp.1574~1580 (2008)[DOI]
143. Ugander M, "Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology", Eur Heart J, 33, pp.1268~1278 (2012)[DOI]
144. Neilan TG, "Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines", Am J Cardiol, 110, pp.1679~1686 (2012)[DOI]
145. Grover S, "Early and late changes in markers of aortic stiffness with breast cancer therapy", Intern Med J, 45, pp.140~147 (2015)[DOI]
146. Chaosuwannakit N, "Aortic stiffness increases upon receipt of anthracycline chemotherapy", J Clin Oncol, 28, pp.166~172 (2010)[DOI]
147. Vasu S, "Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance", J Cardiovasc Magn Reson, 15, pp.66~ (2013)[DOI]
148. Schwartz RG, "Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively", J Nucl Cardiol, 20, pp.443~464 (2013)[DOI]
149. de Geus-Oei LF, "Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity", J Nucl Med Technol, 41, pp.170~181 (2013)[DOI]
150. Altena R, "Cardiovascular toxicity caused by cancer treatment: strategies for early detection", Lancet Oncol, 10, pp.391~399 (2009)[DOI]
151. Schwartz RG, "Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography", Am J Med, 82, pp.1109~1118 (1987)[DOI]
152. Groch MW, "Planar imaging versus gated blood-pool SPECT for the assessment of ventricular performance: a multicenter study", J Nucl Med, 42, pp.1773~1779 (2001)
153. Castro P, "Relationship between mechanical and metabolic dyssynchrony with left bundle branch block: evaluation by 18-fluorodeoxyglucose positron emission tomography in patients with nonischemic heart failure", J Heart Lung Transplant, 31, pp.1096~1101 (2012)[DOI]
154. Perrone-Filardi P, "Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal", Heart, 97, pp.1828~1833 (2011)[DOI]
155. Carrio I, "Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity", J Nucl Med, 36, pp.2044~2049 (1995)
156. Carrio I, "Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies", J Nucl Med, 34, pp.1503~1507 (1993)
157. Estorch M, "Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies", J Clin Oncol, 11, pp.1264~1268 (1993)[DOI]
158. Jacobson AF, "Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIREHF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study", J Am Coll Cardiol, 55, pp.2212~2221 (2010)[DOI]
159. Saito K, "Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings", Ann Nucl Med, 17, pp.481~488 (2003)[DOI]
160. Giedd KN, "Fatty acid imaging of the heart", Curr Cardiol Rep, 13, pp.121~131 (2011)[DOI]
161. Behr TM, "Trastuzumab and breast cancer", N Engl J Med, 345, pp.995~996 (2001)[DOI]
162. Gaykema SB, "(111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment", Mol Imaging (2014)[DOI]
163. Perik PJ, "Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer", J Clin Oncol, 24, pp.2276~2282 (2006)[DOI]
164. Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
165. Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)[DOI]
166. Yancy CW, "2016 ACC", AHA, AHA guideline for the management of heart failure: a report of the American College of Cardiology, pp.American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America, J Am Coll Cardiol[DOI]
167. Cardinale D, "Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition", Circulation, 114, pp.2474~2481 (2006)[DOI]
168. Ewer MS, "Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment", J Clin Oncol, 23, pp.7820~7826 (2005)[DOI]
169. Arteaga CL, "Treatment of HER2-positive breast cancer: current status and future perspectives", Nat Rev Clin Oncol, 9, pp.16~32 (2011)
170. Goldhirsch A, "2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial", Lancet, 382, pp.1021~1028 (2013)[DOI]
171. Swain SM, "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study", Lancet Oncol, 14, pp.461~471 (2013)[DOI]
172. Jensen BV, "Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients", Ann Oncol, 13, pp.699~709 (2002)[DOI]
173. Cianci G, "Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity", Br J Cancer, 88, pp.1507~1509 (2003)[DOI]
174. Fihn SD, "2014 ACC", AHA, PCNA, pp.SCAI, STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology[DOI]
175. Amsterdam EA, "2014 AHA", ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology, Circulation, pp.2014, 130[DOI]
176. Iannaccone M, "Optimal medical therapy in patients with malignancy undergoing percutaneous coronary intervention for acute coronary syndrome: a BleeMACS sub-study", Am J Cardiovasc Drugs, 17, pp.61~71 (2017)[DOI]
177. Vieira RD, "Cancer-related deaths among different treatment options in chronic coronary artery disease: results of a 6-year follow-up of the MASS II study", Coron Artery Dis, 23, pp.79~84 (2012)[DOI]
178. Iliescu CA, "SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista)", Catheter Cardiovasc Interv, 87, pp.E202~E223 (2016)[DOI]
179. Strevel EL, "Molecularly targeted oncology therapeutics and prolongation of the QT interval", J Clin Oncol, 25, pp.3362~3371 (2007)[DOI]
180. Farmakis D, "Insights into onco-cardiology: atrial fibrillation in cancer", J Am Coll Cardiol, 63, pp.945~953 (2014)[DOI]
181. Bates SE, "Challenges of evaluating the cardiac effects of anticancer agents", Clin Cancer Res, 12, pp.3871~3874 (2006)[DOI]
182. January CT, "2014 AHA", ACC, American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2014[DOI]
183. Lip GY, "Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. a joint consensus document from the ESC heart failure association and the ESC working group on thrombosis", Eur J Heart Fail, 14, pp.681~695 (2012)[DOI]
184. Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)[DOI]
185. Mathur P, "Atrial fibrillation in hematologic malignancies, especially after autologous hematopoietic stem cell transplantation: review of risk factors, current management, and future directions", Clin Lymphoma Myeloma Leuk, 16, pp.70~75 (2016)[DOI]
186. Xiang E, "Anticoagulation prescribing patterns in patients with cancer", J Thromb Thrombolysis, 45, pp.89~98 (2018)[DOI]
187. Laube ES, "Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer", Am J Cardiol, 120, pp.213~217 (2017)[DOI]
188. James PA, "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)", JAMA, 311, pp.507~520 (2014)[DOI]
189. Lackland DT, "Hypertension: joint national committee on detection, evaluation, and treatment of high blood pressure guidelines", Curr Opin Neurol, 26, pp.8~12 (2013)[DOI]
190. Lyman GH, "Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014", J Clin Oncol, 33, pp.654~656 (2015)[DOI]
191. Khorana AA, "Risk assessment and prophylaxis for VTE in cancer patients", J Natl Compr Canc Netw, 9, pp.789~797 (2011)[DOI]
192. Akl EA, "Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer", Cochrane Database Syst Rev (2014)[DOI]
193. Prins MH, "Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies", Thromb J, 11, pp.21~ (2013)[DOI]
194. Schulman S, "Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer", Thromb Haemost, 114, pp.150~157 (2015)[DOI]
195. Farge D, "International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer", J Thromb Haemost, 11, pp.56~70 (2013)[DOI]
196. Papanikolaou J, "Thrombolysis for massive pulmonary embolism in a patient with hemorrhagic shock", Am J Respir Crit Care Med, 194, pp.e15~e16 (2016)[DOI]
197. O'Connell CL, "Approach to the management of incidental venous thromboembolic events in patients with cancer", J Natl Compr Canc Netw, 12, pp.1557~1560 (2014)[DOI]
198. Galie N, "2015 ESC", ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), 2016, pp.37, 67~119
199. Ranchoux B, "Chemotherapy-induced pulmonary hypertension: role of alkylating agents", Am J Pathol, 185, pp.356~371 (2015)[DOI]
200. Adler Y, "2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)", Eur Heart J, 36, pp.2921~2964 (2015)[DOI]
201. Lestuzzi C, "2015 update on the diagnosis and management of neoplastic pericardial disease", Expert Rev Cardiovasc Ther, 13, pp.377~389 (2015)[DOI]
202. Raval J, "The role of colchicine in pericarditis--a systematic review and meta-analysis of randomised trials", Heart Lung Circ, 24, pp.660~666 (2015)[DOI]
203. El Haddad D, "Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion", J Am Coll Cardiol, 66, pp.1119~1128 (2015)[DOI]
204. Feldman D, "The 2013 International Society for heart and lung transplantation guidelines for mechanical circulatory support: executive summary", J Heart Lung Transplant, 32, pp.157~187 (2013)[DOI]

관련 논문AI추천